Search
Certolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigationaldone directly in bacterial hosts such as _E. coli_. … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]
Products: CIMZIA 200 MG ILO IN FER, CIMZIA 200MG ILO IN FERTenecteplase
go.drugbank.com/drugs/DB00031ApprovedInvestigationalamino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigational[L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life. … [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production
Fenoldopam
go.drugbank.com/drugs/DB00800ApprovedA dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
L-tartaric acid
go.drugbank.com/drugs/DB09459ApprovedTartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics
Mixtures: E-Z-gas 2 GranulesEtonogestrel
go.drugbank.com/drugs/DB00294ApprovedInvestigational[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Acenocoumarol
go.drugbank.com/drugs/DB01418ApprovedInvestigationalPatients on acenocoumarol are prohibited from giving blood. … Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase.
Uridine triacetate
go.drugbank.com/drugs/DB09144ApprovedIt is provided in the prodrug form as uridine triacetate as this form delivers 4- to 6-fold more uridine into the systemic circulation compared to equimolar doses of uridine itself. … When administered as the prodrug uridine triacetate, uridine can be used by essentially all cells to make uridine nucleotides, which compensates for the genetic deficiency in synthesis in patients with
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]
Sulopenem etzadroxil
go.drugbank.com/drugs/DB16335ApprovedInvestigational[L51858] It is administered in combination with [probenecid] in order to increase antibiotic exposure.[L51768] … [L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.